Items where authors include "Karunanithi, K."

Article

Garderet, L., Gras, L., Koster, L. et al. (23 more authors) (2024) Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 109 (8). ISSN 0390-6078

Jenner, M.W., Pawlyn, C., Davies, F.E. et al. (15 more authors) (2023) The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma XI’, a multicentre, open‐label, randomised, phase III trial. British Journal of Haematology, 201 (2). pp. 267-279. ISSN 0007-1048

Jackson, G.H., Pawlyn, C., Cairns, D.A. et al. (20 more authors) (2021) Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. PLOS Medicine, 18 (1). e1003454. ISSN 1549-1277

Proceedings Paper

Jackson, G.H., Davies, F.E., Pawlyn, C. et al. (18 more authors) (2016) Lenalidomide is a highly effective maintenance therapy in myeloma patients of all ages; results of the Phase III Myeloma XI Study. In: Blood. 58th ASH Annual Meeting, 03-06 Dec 2016, San Diego, CA, USA. American Society of Hematology .

Pawlyn, C., Davies, F.E., Kaiser, M.F. et al. (18 more authors) (2016) Primary IMiD refractory myeloma; results from 3894 patients treated in the Phase III Myeloma XI Study. In: Blood. 58th ASH Annual Meeting, 03-06 Dec 2016, San Diego, CA, USA. American Society of Hematology .

Jackson, G.H., Davies, F.E., Pawlyn, C. et al. (18 more authors) (2016) Response adapted induction treatment improves outcomes for myeloma patients; results of the Phase III Myeloma XI Study. In: Blood. 58th ASH Annual Meeting, 03-06 Dec 2016, San Diego, CA, USA. American Society of Hematology .